Home LiteratureArticle Details
PMID: 18704200 Published · ppublish English Journal Article

Activated PPARgamma Targets Surface and Intracellular Signals That Inhibit the Proliferation of Lung Carcinoma Cells.

PPAR research ·Vol. 2008 ·2008-00-00 ·Pages 254108

Han SW, Roman J

Abstract

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. Their discovery in the 1990s provided insights into the cellular mechanisms involved in the control of energy homeostasis, the regulation of cell differentiation, proliferation, and apoptosis, and the modulation of important biological and pathological processes related to inflammation and cancer biology, among others. Since then, PPARs have become an exciting target for the development of therapies directed at many disorders including cancer. PPARs are expressed in many tumors including lung cancer, and their function has been linked to the process of carcinogenesis. Consequently, intense research is being conducted in this area with the hope of discovering new PPAR-related therapeutic targets for the treatment of lung cancer. This review summarizes the research being conducted in this area, and focuses on the mechanisms by which a member of this family (PPARgamma) is believed to affect lung tumor cell biology.

Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Han Shou Wei
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Emory University School of Medicine, 615 Michael Street Suite 205, Atlanta, GA 30322, USA.
Roman Jesse
References (68)
68 references, click to expand
  1. Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-gamma by flavonoids in mouse macrophages.
    FEBS Lett. 2001 May 4;496(1):12-8 PMID: 11343698
  2. Quantification of PPAR-gamma protein in monocyte/macrophages from healthy smokers and non-smokers: a possible direct effect of nicotine.
    Life Sci. 2007 Aug 23;81(11):906-15 PMID: 17765929
  3. The many faces of PPARgamma.
    Cell. 2005 Dec 16;123(6):993-9 PMID: 16360030
  4. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma.
    Cell. 1998 Apr 17;93(2):229-40 PMID: 9568715
  5. Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth.
    Biochem Biophys Res Commun. 2004 Feb 20;314(4):1093-9 PMID: 14751245
  6. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Cancer Res. 2006 Jan 1;66(1):315-23 PMID: 16397245
  7. Overview and state of the art in the management of lung cancer.
    Oncology (Williston Park). 2004 Jun;18(7 Suppl 4):3-9 PMID: 15255162
  8. Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells.
    J Biol Chem. 2006 Oct 6;281(40):29614-24 PMID: 16882662
  9. Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.
    Mol Pharmacol. 2007 Sep;72(3):674-85 PMID: 17535976
  10. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells.
    Oncogene. 2002 Mar 28;21(14):2171-80 PMID: 11948400
  11. Peroxisome proliferator-activated receptor-gamma ligands inhibit alpha5 integrin gene transcription in non-small cell lung carcinoma cells.
    Am J Respir Cell Mol Biol. 2005 Apr;32(4):350-9 PMID: 15677767
  12. PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo.
    Invest New Drugs. 2008 Jun;26(3):283-8 PMID: 18161004
  13. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).
    J Biol Chem. 1995 Jun 2;270(22):12953-6 PMID: 7768881
  14. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.
    Cancer Res. 1999 Nov 15;59(22):5671-3 PMID: 10582681
  15. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand.
    Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2340-5 PMID: 15701701
  16. PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells.
    Cancer Biol Ther. 2007 Jan;6(1):99-106 PMID: 17172826
  17. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
    Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9 PMID: 9932726
  18. In utero nicotine exposure alters fetal rat lung alveolar type II cell proliferation, differentiation, and metabolism.
    Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L323-33 PMID: 17215434
  19. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma.
    Curr Opin Genet Dev. 1995 Oct;5(5):571-6 PMID: 8664544
  20. Two new furanoditerpenes from Saururus chinenesis and their effects on the activation of peroxisome proliferator-activated receptor gamma.
    J Nat Prod. 2002 Apr;65(4):616-7 PMID: 11975517
  21. PPARgamma in monocytes: less pain, any gain?
    Cell. 1998 Apr 17;93(2):153-5 PMID: 9568708
  22. Hepatic dysfunction associated with troglitazone.
    N Engl J Med. 1998 Mar 26;338(13):916-7 PMID: 9518284
  23. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth.
    Am J Physiol Gastrointest Liver Physiol. 2003 Jul;285(1):G20-30 PMID: 12660143
  24. Expression of a peroxisome proliferator-activated receptor gamma 1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress.
    Clin Cancer Res. 2007 May 1;13(9):2577-83 PMID: 17473186
  25. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition.
    Cancer Res. 2005 May 15;65(10):4181-90 PMID: 15899809
  26. Biology of PPAR gamma in cancer: a critical review on existing lacunae.
    Curr Mol Med. 2007 Sep;7(6):532-40 PMID: 17896990
  27. Fibronectin. A versatile matrix protein with roles in thoracic development, repair and infection.
    Chest. 1992 Jun;101(6):1663-73 PMID: 1534744
  28. Rosiglitazone, an Agonist of PPARgamma, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2.
    PPAR Res. 2007;2007:29632 PMID: 17597835
  29. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein.
    Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7614-9 PMID: 9636198
  30. Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer.
    Anticancer Res. 2001 Jul-Aug;21(4A):2471-6 PMID: 11724309
  31. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties.
    J Biol Chem. 1998 Dec 4;273(49):32679-84 PMID: 9830009
  32. Genetic variants in peroxisome proliferator-activated receptor-gamma gene are associated with risk of lung cancer in a Chinese population.
    Carcinogenesis. 2008 Feb;29(2):342-50 PMID: 18187557
  33. Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy.
    J Investig Med. 2008 Feb;56(2):528-33 PMID: 18317436
  34. PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer.
    Neoplasia. 2005 Mar;7(3):294-301 PMID: 15799829
  35. PPAR gamma and human metabolic disease.
    J Clin Invest. 2006 Mar;116(3):581-9 PMID: 16511590
  36. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone.
    Int J Cancer. 2006 Feb 1;118(3):773-9 PMID: 16094629
  37. The organization, promoter analysis, and expression of the human PPARgamma gene.
    J Biol Chem. 1997 Jul 25;272(30):18779-89 PMID: 9228052
  38. Emerging roles of PPARs in inflammation and immunity.
    Nat Rev Immunol. 2002 Oct;2(10):748-59 PMID: 12360213
  39. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.
    J Cell Biochem. 2005 Nov 1;96(4):760-74 PMID: 16149072
  40. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer.
    Oncogene. 2004 Jan 8;23(1):100-8 PMID: 14712215
  41. Integrin-linked kinase: a cancer therapeutic target unique among its ILK.
    Nat Rev Cancer. 2005 Jan;5(1):51-63 PMID: 15630415
  42. Phenolics with PPAR-gamma ligand-binding activity obtained from licorice (Glycyrrhiza uralensis roots) and ameliorative effects of glycyrin on genetically diabetic KK-A(y) mice.
    Bioorg Med Chem Lett. 2003 Dec 15;13(24):4267-72 PMID: 14643306
  43. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.
    Nature. 1998 Jan 1;391(6662):82-6 PMID: 9422509
  44. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells.
    J Cell Physiol. 2006 Nov;209(2):428-38 PMID: 16883598
  45. Nicotine and fibronectin expression in lung fibroblasts: implications for tobacco-related lung tissue remodeling.
    FASEB J. 2004 Sep;18(12):1436-8 PMID: 15247149
  46. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis.
    J Clin Invest. 2002 Oct;110(7):923-32 PMID: 12370270
  47. Influence of ciglitazone on A549 cells growth in vitro and in vivo and mechanism.
    J Huazhong Univ Sci Technolog Med Sci. 2006;26(1):36-9 PMID: 16711003
  48. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.
    J Clin Oncol. 2007 Apr 20;25(12):1476-81 PMID: 17442990
  49. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter.
    FEBS Lett. 1998 Oct 30;438(1-2):55-60 PMID: 9821958
  50. Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
    Mol Cell Endocrinol. 2005 May 12;235(1-2):21-9 PMID: 15866424
  51. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.
    Lancet. 2007 Jun 9;369(9577):1929-37 PMID: 17544497
  52. 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors.
    Anticancer Drugs. 2007 Jan;18(1):65-78 PMID: 17159504
  53. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways.
    Mol Cancer Ther. 2006 Feb;5(2):430-7 PMID: 16505118
  54. PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression.
    Lung Cancer. 2006 Mar;51(3):297-301 PMID: 16386327
  55. Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade.
    Lung Cancer. 2002 Jun;36(3):249-55 PMID: 12009233
  56. Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1.
    Am J Physiol Lung Cell Mol Physiol. 2005 Sep;289(3):L419-28 PMID: 15908479
  57. n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells.
    Biochim Biophys Acta. 2007 May;1771(5):576-89 PMID: 17459764
  58. Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta.
    J Biol Chem. 2005 Sep 30;280(39):33240-9 PMID: 16061473
  59. Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma.
    Br J Cancer. 2005 Jan 17;92(1):113-9 PMID: 15583697
  60. Role of nuclear receptors in lung tumourigenesis.
    Eur J Cancer. 2005 Nov;41(16):2561-8 PMID: 16199155
  61. Arachidonic acid suppresses growth of human lung tumor A549 cells through down-regulation of ALDH3A1 expression.
    Free Radic Biol Med. 2006 Jun 1;40(11):1929-38 PMID: 16716894
  62. Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells.
    Prostaglandins Leukot Essent Fatty Acids. 2007 Jul;77(1):51-8 PMID: 17697767
  63. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells.
    Clin Cancer Res. 2004 Mar 15;10(6):1911-9 PMID: 15041706
  64. PPAR gamma signaling exacerbates mammary gland tumor development.
    Genes Dev. 2004 Mar 1;18(5):528-40 PMID: 15037548
  65. Synergy between PPARgamma ligands and platinum-based drugs in cancer.
    Cancer Cell. 2007 May;11(5):395-406 PMID: 17482130
  66. Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro.
    Biochem J. 2004 Nov 15;384(Pt 1):149-57 PMID: 15320868
  67. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.
    Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11 PMID: 9671760
  68. 100 years of lung cancer.
    Respir Med. 2006 Dec;100(12):2073-84 PMID: 17056245
Article Info
Journal
PPAR research
Abbr.
PPAR Res
ISSN
1687-4757
DOI
10.1155/2008/254108
Published
2008-00-00
Pages
254108
Language
English
Region
United States
NLM ID
101269101
PMCID
PMC2515882
Grants
NCI NIH HHS · K22 CA123104 · United States
External Links
PubMed source DOI: 10.1155/2008/254108 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2